· Periodic Report
Q3 operating loss of KRW 16.3 billion, larger than a year earlier
Olix sold KRW 2.2 billion in Q3 and lost KRW 16.3 billion from its main business, versus sales of KRW 2.9 billion and a KRW 8.3 billion loss a year earlier.
226950 · KOSDAQ · Based on DART filings
2 total · 20 per page
· Periodic Report
Olix sold KRW 2.2 billion in Q3 and lost KRW 16.3 billion from its main business, versus sales of KRW 2.9 billion and a KRW 8.3 billion loss a year earlier.
The New Zealand ethics committee approved on Nov 10, 2026 on re-review the OLX10212 Phase 2a application it had rejected on Oct 12, 2026.
Get app alerts for new disclosures from OliX Pharmaceuticals, Inc..